Contributions
Abstract: EP1706
Type: Poster Sessions
Abstract Category: Therapy - Others
Introduction: OCR is the only disease-modifying therapy (DMT) approved for both relapsing and primary progressive forms of multiple sclerosis (MS). Limited information is available on patients initiating OCR in the real world.
Objective: To characterize patients initiating ocrelizumab (OCR) in a real-world setting.
Methods: This study used Pharmetrics Plus, a large US insurance claims database, to identify patients initiating OCR (“initiators”) between April and December 2017. Patients using OCR were identified if they had either: 1) miscellaneous J codes or temporary OCR code C9399 with CPT codes indicating infusion (IV) procedures, and an MS diagnosis or previous MS DMT history, or, 2) OCR NDC code. Patients were included if they had at least 2 IVs 12 to 18 days apart, without other DMTs within 6 months of initiation. At least 12 months continuous enrollment prior to OCR initiation was required. Demographic and clinical characteristics, including DMT use prior to OCR, Charlson Comorbidity Index (CCI), MS-related symptoms, and relapse rate were reported for the year prior to OCR initiation and stratified by prior use of DMT and initiation quarter.
Results: A total of 838 OCR initiators were identified, representing 21.9% of all MS patients who initiated a DMT during the same period. The mean (SD) age for OCR initiators was 49.2 (11.0) years, CCI score was 0.39 (0.84), 63.2% were female, and the most frequent MS symptoms reported were fatigue (33.8%) and neurogenic bladder (13.6%). Approximately 33.4% of OCR initiators had a relapse in the year prior, with a pre-index annual relapse rate of 0.52. 34.7% of initiators had no DMT use in the prior year (“untreated”). Among OCR initiators switching from another DMT (“switchers”), 46.4%, 19.6%, and 34.0% switched from oral, injectable, and other IV DMTs, respectively. From Q2 to Q4 2017, the % of untreated OCR initiators increased from 30.4% to 41.3%, and the % of switchers previously treated with injectables increased from 15.2% to 29.5%. The mean CCI decreased from 0.45 to 0.33.
Conclusions: To our knowledge, this is the first real-world study documenting the characteristics of OCR early adopters. As real-world data on OCR mature, comparative-effectiveness research will examine real-world outcomes and should address the changing characteristics of OCR initiators over time.
Disclosure: Sponsored by Genentech, Inc. N.J. Engmann is an employee of Genentech, Inc., and a shareholder of F. Hoffmann-La Roche Ltd; E. Yang is an employee of Genentech, Inc., and a shareholder of F. Hoffmann-La Roche Ltd; L. Julian is an employee of Genentech, Inc., and a shareholder of F. Hoffmann-La Roche Ltd; W.S. Yeh is an employee of Genentech, Inc., and a shareholder of F. Hoffmann-La Roche Ltd; J. Whiteley is an employee of Genentech, Inc., and a shareholder of F. Hoffmann-La Roche Ltd.
Abstract: EP1706
Type: Poster Sessions
Abstract Category: Therapy - Others
Introduction: OCR is the only disease-modifying therapy (DMT) approved for both relapsing and primary progressive forms of multiple sclerosis (MS). Limited information is available on patients initiating OCR in the real world.
Objective: To characterize patients initiating ocrelizumab (OCR) in a real-world setting.
Methods: This study used Pharmetrics Plus, a large US insurance claims database, to identify patients initiating OCR (“initiators”) between April and December 2017. Patients using OCR were identified if they had either: 1) miscellaneous J codes or temporary OCR code C9399 with CPT codes indicating infusion (IV) procedures, and an MS diagnosis or previous MS DMT history, or, 2) OCR NDC code. Patients were included if they had at least 2 IVs 12 to 18 days apart, without other DMTs within 6 months of initiation. At least 12 months continuous enrollment prior to OCR initiation was required. Demographic and clinical characteristics, including DMT use prior to OCR, Charlson Comorbidity Index (CCI), MS-related symptoms, and relapse rate were reported for the year prior to OCR initiation and stratified by prior use of DMT and initiation quarter.
Results: A total of 838 OCR initiators were identified, representing 21.9% of all MS patients who initiated a DMT during the same period. The mean (SD) age for OCR initiators was 49.2 (11.0) years, CCI score was 0.39 (0.84), 63.2% were female, and the most frequent MS symptoms reported were fatigue (33.8%) and neurogenic bladder (13.6%). Approximately 33.4% of OCR initiators had a relapse in the year prior, with a pre-index annual relapse rate of 0.52. 34.7% of initiators had no DMT use in the prior year (“untreated”). Among OCR initiators switching from another DMT (“switchers”), 46.4%, 19.6%, and 34.0% switched from oral, injectable, and other IV DMTs, respectively. From Q2 to Q4 2017, the % of untreated OCR initiators increased from 30.4% to 41.3%, and the % of switchers previously treated with injectables increased from 15.2% to 29.5%. The mean CCI decreased from 0.45 to 0.33.
Conclusions: To our knowledge, this is the first real-world study documenting the characteristics of OCR early adopters. As real-world data on OCR mature, comparative-effectiveness research will examine real-world outcomes and should address the changing characteristics of OCR initiators over time.
Disclosure: Sponsored by Genentech, Inc. N.J. Engmann is an employee of Genentech, Inc., and a shareholder of F. Hoffmann-La Roche Ltd; E. Yang is an employee of Genentech, Inc., and a shareholder of F. Hoffmann-La Roche Ltd; L. Julian is an employee of Genentech, Inc., and a shareholder of F. Hoffmann-La Roche Ltd; W.S. Yeh is an employee of Genentech, Inc., and a shareholder of F. Hoffmann-La Roche Ltd; J. Whiteley is an employee of Genentech, Inc., and a shareholder of F. Hoffmann-La Roche Ltd.